Medicine Pricing: Patients Deserve Transparency, Not Just an MRP – Gs Gopal Raaj.

The wide gap between the actual manufacturing cost of medicines and their printed Maximum Retail Price (MRP) raises serious questions about transparency and accountability in India’s pharmaceutical industry.

If a medicine costs just ₹10 to manufacture but carries an MRP of ₹100, what justifies the tenfold difference? Patients have every right to know how the prices of medicines, particularly essential and life-saving drugs, are determined.

While pharmaceutical companies have legitimate expenses, including research, clinical trials, regulatory compliance, distribution and business operations, these factors should not become a reason for excessive pricing or unreasonable profit margins.

The government must consider stronger transparency measures, including appropriate disclosure of medicine pricing structures and closer monitoring of pharmaceutical profit margins. Patients should not be left in the dark about the pricing of medicines on which their lives depend.

Healthcare is not merely a commercial business. It is a service closely connected with human life, dignity and survival. Pharmaceutical companies deserve reasonable returns for their investments and innovations, but social responsibility must remain equally important.

A life-saving medicine should not become a financial burden for the very people who depend on it to survive. The time has come for the pharmaceutical industry and policymakers to put patient welfare at the centre of medicine pricing.

– G.S. Gopal Raaj
Editor – City Today News & TJ Vision Media

City Today News 9341997936

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.